During our 4-month Feasibility Study several activities have been carried out. First, the technical specifications of ColiSense’s subsystems have been defined. Following, a risk analysis has been conducted to ensure that no issues have been left aside and that future development will be with a low and controlled risk. Our team prepared a complete Execution Plan for the development and exploitation of ColiSense; we also identified the most beneficial partners to support us in the execution and exploitation of the Phase 2 project. Regarding commercial feasibility assessment, we have focused on the potential new markets which has allowed us to prepare our marketing and pricing strategy. Furthermore, a complete Freedom-to-Operate was performed and confirmed 1) the novelty of the ColiSense and 2) the absence of existing thread for its commercialization. Finally, financial projections for the 2021-2026 period have been calculated, and we expect a highly positive turnover.